tbuckley/cabot-search huggingface dataset:
Virus of Avian Erythroblastosis. I. Titration of Infectivity&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: Eckert, Edward A., Beard, Dorothy, Beard, J. W.
Journal: JNCI Journal of the National Cancer Institute (1956)

Journal Article Virus of Avian Erythroblastosis. I. Titration of Infectivity Get access Edward A. Eckert, Edward A. Eckert Department of Surgery, Duke University School of Medicine, Durham, N. C. Search for other works by this author on: Oxford Academic PubMed Google Scholar Dorothy Beard, Dorothy Beard Department of Surgery, Duke University School of Medicine, Durham, N. C. Search for other works by this author on: Oxford Academic PubMed Google Scholar J. W. Beard J. W. Beard Department of Surgery, Duke University School of Medicine, Durham, N. C. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 16, Issue 5, April 1956, Pages 1099–1120, https://doi.org/10.1093/jnci/16.5.1099 Published: 01 April 1956 Article history Received: 20 September 1955 Published: 01 April 1956
Do we need a new word to supplement "hallucination"?
Authors: I Stevenson
Journal: American Journal of Psychiatry (1983)

The word "hallucination" was used originally (and with etymological correctness) to refer to the unshared sensory experiences of persons who are mentally ill. However, many persons who are not mentally ill also have unshared sensory experiences. A few of these convey information paranormally, but the longstanding association of "hallucination" with mental illness inhibits many persons who have such experiences from reporting them so that they can be studied. The author suggests a new word, "idiophany," to designate all unshared sensory experiences. The word "hallucination" could then be restricted, as it originally was, to the unshared sensory experiences of the mentally ill.
PTH-054 The rising incidence of early-onset paediatric inflammatory bowel disease (PARIS A1A) in scotland since 1981: a national, population-based, cohort study
Authors: P Henderson, FL Cameron, F Jagger, R Hansen, HE Drummond, E Reynish, S Loganathan, RK Russell, J Satsangi, DC Wilson
Journal: Gut (2015)

<h3>Introduction</h3> Although worldwide and Scottish<sup>1</sup>data has clearly shown a persistent rise in paediatric inflammatory bowel disease (PIBD), population-based trends in early-onset incident PIBD (i.e. diagnosed before their 10<sup>th</sup>birthday; Paris A1a) are lacking. We aimed to evaluate the incidence of PIBD A1a between 1981–2013 using a complete national cohort study. <h3>Method</h3> National data from previously published incident cohorts of PIBD in Scotland during 1981–1995 and 2003–2008 were first examined; prospectively collected incident cases from 2009–2013 were also included. Patients were only included following thorough case-note review. As IBD-unclassified (IBDU) was not a recognised IBD type in the earlier cohorts, the classification of non-Crohn's colitis (NCC; i.e. ulcerative colitis and IBDU combined) was introduced to allow comparisons. Incidence rates were calculated using publicly available population data and trends across cohorts calculated using Poisson regression. <h3>Results</h3> 402 A1a PIBD patients were identified with a slight (53%) male preponderance; approximately 60% were Crohn's disease (CD) with the remainder NCC. There was a steady increase in incident cases with 39 patients diagnosed between 1981–1985 and 134 between 2008–2013. The adjusted incidence of A1a PIBD rose from 1.2/100,000/yr (95% CI 0.8–1.6) (1981–1985) to 4.1/100,000/yr (95% CI 3.5–4.7) (2008–2013) (p &lt; 0.001); the incidence rate remainded stable in the most recent epoch (2008–2013). The incidence of the 0–5 yr group rose from 0.7/100,000/yr (1981–1985) to 2.0/100,000/yr (2008–2013) (p = 0.017) compared to an incidence rise of 2.0/100,000/yr (1981–1985) to 7.2/100,000/yr (2008–2013) (p &lt; 0.001) in the 6–9 yr group. The incident rate ratio between the first and last epochs were 2.9 (95% CI 1.5–6.4) and 3.6 (95% CI 2.3–5.8) in the 0–5 yr and the 6–9 yr age groups respectively. There were no significant sex differences across any group and both the CD and NCC groups showed similar trends. <h3>Conclusion</h3> Using population-based Scottish data from the previous four decades we have shown that early-onset PIBD (A1a) has shown a significant rise in incidence, with three-fold increases seen in both the very-early-onset (0–5 yr) and 6–9 yr age groups. However, incidence rates seem to have stabilised in the last decade, despite a sustained rise in overall PIBD.<sup>1</sup>Further examination of these young patients may provide clues to IBD aetiopathogenesis. <h3>Disclosure of interest</h3> None Declared. <h3>References</h3> Henderson P, <i>et al</i>.<i>J Crohns Colitis</i>. 2015;<b>9</b>(S1):S2 Benchimol, <i>et al</i>. Gastroenterology 2014;147(4):803–813
Case 11-1989
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, Richard A. Moscicki, Robert B. Colvin
Journal: New England Journal of Medicine (1989)

Presentation of CaseA 57-year-old woman was admitted to the hospital because of worsening skin ulcerations and decreasing renal function.There was a 14-year history of pretibial petechiae. Evaluation at the time of onset showed that a test for antinuclear antibodies was positive in a titer of 1:64 (homogeneous and speckled) and a test for rheumatoid factor was positive. Microscopical examination of a biopsy specimen of the skin showed infiltration by neutrophils, with red-cell extravasation, but no fibrinoid necrosis; the appearance was believed consistent with vasculitis but not diagnostic. Thereafter the patient had intermittent flares of activity in the cutaneous . . .
PTH-239 Travelling with children on home parenteral nutrition
Authors: C Mantegazza, V LaVela, S Hill, J Köglmeier
Journal: Gut (2015)

<h3>Introduction</h3> Home parenteral nutrition (PN) is a well established therapy in children with intestinal failure. Modern PN management allows most paediatric patients to participate in age appropriate activities such as physcial exercise, play and mainstream education. Spending time away from home and going on holiday may be limited as the intravenous nutrition is infused over many hours on most if not all days of the week. We aimed to identify socio-demographic and illness-specific variables which influence if and how families with children on home PN travel. <h3>Method</h3> A standardised questionnaire together with an information leaflet was sent to all 40 children participating in the home PN program of a large tertiary centre intestinal failure unit in the United Kingdom and written consent was obtained at the next outpatient clinic visit. Depending on whether the family had/had not been on holiday since their child had been started on home PN specific questions were asked to understand the reasons for not travelling or to get more information about the individual travel experience. <h3>Results</h3> A total of 30/40 (75%) children were enrolled, 20/30 (66.6%) went at least once on holiday and 5/30 (16.6%) travelled more than once per year. The majority (14/30; 70%) travelled to destinations outside Britain. Going on vacation was more common the longer the child had been on home PN (travellers: median 48 months/ non travellers: median 30 months, p 0.022). However, there was no association with the length of time tolerated without PN, tolerance of enteral feeds or child’s age. Ten families decided against a holiday over fear it might be too difficult to arrange or the child’s unstable underlying medical condition. Most parents who went on vacation had a good or worthy experience (16/20; 80%) and the majority wanted to travel again (19/20; 95%). The biggest obstacle to overcome reported was to transport the intravenous nutrition bags due to their weight and required storage space. <h3>Conclusion</h3> A significant proportion of families chose to go on holiday away from home despite their child being on home PN. The experience is considered good by most which can help to encourage other parents in the future. <h3>Disclosure of interest</h3> None Declared. <h3>References</h3> PINNT Holiday Guidelines: Travelling with Parenteral or Enteral Nutrition Therapy, http://pinnt.com/Support-for-Members.aspx Barclay AR, Henderson P, Gowen H, Puntis J, BIGS collaborators. The continued rise of paediatric home parenteral nutrition use: Implications for service and the improvement of longitudinal data collection. <i>Clin Nutr</i>2014 Nov 20 pii: S0261-5614(14)00290–8
FRI0473 Is Male Sex a Negative Predictor for Systemic Sclerosis? Experience of a Eustar Center
Authors: L. Groseanu, T. Gudu, A. Balanescu, D. Predeteanu, F. Berghea, D. Opris, I. Saulescu, A. Borangiu, C. Constantinescu, V. Bojinca, M.-M. Negru, M. Abobului, R. Ionescu
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Systemic sclerosis (SSc) has a female predominance, however, little is understood about the effect of sex on SSc manifestations and survival. <h3>Objectives</h3> The objectives of our study were to evaluate differences in disease manifestations, and survival rates between males and females with SSc. <h3>Methods</h3> A retrospective cohort study of EUSTAR center 096 was conducted to evaluate sex-based differences in disease manifestations and survival. A complete baseline evaluation of all patients was done according to MEDS evaluation sheets. A complete follow-up was done every year. All calculations were performed with SPSS Statistics 20.0. Student t-test or Mann-Whitney test and chi-square test were used to evaluate differences for variables. Pearson9s bivariate correlation or Spearman9s rank correlation coefficient were used to evaluate the association between evaluated variables. The values of r&gt;0.5 and p&lt;0.05 were considered statistically significant. <h3>Results</h3> 90 SSc patients (82 females and 8 males) were followed between JAN 2010 – JAN 2015, with a female:male ratio of 10,25:1. Male patients with systemic sclerosis are younger (48.63±13.46 years compared to 55.63±11.51 years in females), have a shorter disease duration (76±78.13 months compared to 124.11±86.6 months in females), higher Rodnan skin scores (12.38±7.46 compared to 8.85±5.14 in females) with more frequent diffuse skin involvement (62,5% compared to 52,38% in females), develop more frequent digital ulcers (50% compared to 40,29% in females), pulmonary fibrosis (62,5% compared to 35,82% in females), pulmonary arterial hypertension (37,5% compared to 17,91% in females) and have higher Medsger severity score (8.75±3.28 compared to 6.87±3.06); yet none of the above reached statistical significance. Still, activity score seems to be higher in male patients (5,62±3,00 compared to 3,53±1,87, p=0,007). Mortality rates at 5 years was 50% for men compared to 8,95% for women, close to statistical significance (p=0,061). Male sex was associated with increased risk of scleroderma renal crisis (p=0.001). <h3>Conclusions</h3> The differential effect of disease between sexes is small, yet males have increased risk of scleroderma renal crisis compared to females with SSc. <h3>References</h3> Hussein H, Lee P, Chau C, Johnson SR. The effect of male sex on survival in systemic sclerosis.J Rheumatol. 2014;41(11):2193-200 <h3>Disclosure of Interest</h3> None declared
PTH-006 Experience in the use of self-expandable metal stents for the management of variceal haemorrhage
Authors: A Ososanya, H Pick, J Kayani, A Austin, C Salmon, N Taylor, A Lawson
Journal: Gut (2015)

<h3>Introduction</h3> Self-Expandable Metal Stents (SEMS) have been reported in small case series to be effective in controlling bleeding from oesophageal varices. A NICE technology appraisal published in 2008 (updated 2011) approved their use, providing arrangements were in place to audit practice. We describe our experience of SEMS in patients presenting with variceal haemorrhage. <h3>Method</h3> The Royal Derby Hospital has 24/7 provision of emergency endoscopy by a consultant gastroenterologist and TIPSS insertion available within normal working hours. A SEMS (SX-ELLA Danis) was inserted in 15 patients (M:F 12:3, mean age 56, range 29–73) presenting with variceal haemorhage between 2009 and 2014. All stents were inserted under endoscopic guidance. Portal hypertension was due to alcohol induced cirrhosis (n = 14) and Budd Chiari (n = 1). The median Child Pugh score was 11 (B=2/ C =13) and MELD 21 (range 12–35). All patients had band ligation therapy prior to SEMS insertion, with 6 patients having two attempts at endoscopic treatment and 8 patients having a Sengstaken-Blakemore Tube (SBT). The indication for SEMS insertion was ongoing variceal haemorrhage (n = 4), bleeding from band ligation ulceration (n = 7), a combination of the above (n = 2) or complication of SBT insertion (n = 2). SEMS was used as a bridge to TIPSS in 3 patients (though unsuccessful in 2), but TIPSS was felt to be contraindicated in 11 patients due to the severity of hepatic decompensation and in 1 patient due to portal vein thrombosis. <h3>Results</h3> SEMS insertion was successful and immediate haemostasis achieved in all 15 patients. One patient developed aspiration pneumonia, but patients were subsequently nursed at 45° and received a prokinetic, without further incidence of aspiration. Stent migration into the stomach was observed in 3 patients, with partial slip across the gastro-oesophageal junction seen in a further 2 patients. The SEMS were removed from 9 patients after a median of 11 days (range 1–18) without complication. The remaining 6 patients died prior to removal. No patients had evidence of ongoing bleeding while SEMS <i>in situ</i>, but 33% had rebleeding within 30 days of removal. A median of 7 units of blood were transfused pre-SEMS insertion and 2 units post. Patient survival was 40% at 30 days and 27% at 1 year. Amongst survivors at 1 year the median Child Pugh/ MELD score at SEMS insertion was 8.5/ 14 compared to 11/ 24 in those who died. <h3>Conclusion</h3> Our experience shows that SEMS can be safely inserted and effectively achieve haemostasis in patients with refractory haemorrhage from oesophageal varices and in those with bleeding from band ligation induced ulceration. Patient survival was poor, however, due to the severity of hepatic decompensation in the study population. <h3>Disclosure of interest</h3> None Declared.
Update on Multistate Outbreak of Fungal Infections Associated with Contaminated Methylprednisolone Injections, 2012–2014
Authors: Orion Z. McCotter, Rachel M. Smith, Mathew Westercamp, Thomas M. Kerkering, Anurag N. Malani, Robert Latham, Sheree L. Peglow, Rajal K. Mody, Peter G. Pappas, Tom M. Chiller
Journal: MMWR Morbidity and Mortality Weekly Report (2015)

During September 2012, CDC, in collaboration with state and local health departments and the Food and Drug Administration (FDA), investigated a multistate outbreak of fungal meningitis and other infections caused by injections of contaminated methylprednisolone acetate solution (MPA). After this unprecedented outbreak, scientists in the CDC Mycotic Diseases Branch, along with infectious diseases specialists who cared for patients from the outbreak, clinical experts, and public health officials from affected states, have continued to monitor the recovery of affected patients. A long-term follow-up study involving these patients was initiated and is being conducted by the Mycoses Study Group Education and Research Consortium (MSGERC). This update summarizes subsequent information about the current state of the outbreak.
AB0306 Employment and Quality of Life Among Patients with Rheumatoid Arthritis in Four Latin-American Countries
Authors: R.M. Xavier, J. Morales-Torres, D.C.R. Ramos-Remus, P. Chalem, J.F. Molina, J. Duhau, A. Perez-Gilbe, E.M.G. Carnide
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Rheumatoid Arthritis impacts negatively on quality of life and work productivity. There are virtually no data on the employment status and burden of disease in RA patients from Latin-America (LA). <h3>Objectives</h3> To assess the burden of RA on work productivity and health related quality of life in LA patients. <h3>Methods</h3> Consecutive RA patients attending 20 rheumatology outpatient clinics distributed in Argentina, Brazil, Colombia and Mexico were included and completed the following standard questionnaires: Workplace Activity Limitations Scale (WALS), Work Productivity and Activity Impairment (WPAI), Work Limitations Questionnaire (WLQ), EuroQol (EQ-5D) and Short Form 36 Health Survey (SF-36). Sociodemographic data were also collected. <h3>Results</h3> The study included 309 patients, 90% female, mean age of 43 years (SD 9) and disease duration of 8 years (SD 8). At least 40% of patients reported some difficulty in all workplace activities (WALS), especially “crouching, bending, kneeling or working in awkward positions” (83%) and “lifting, carrying or moving objects” (80%). WPAI showed employment rate of 58%, and mean work time lost in a week of 4.3hs (SD 15.8). For WLQ, physical job demands were affected in 42% of patients followed by time demands in 34%. Mean self-evaluated health status using EQ-5D visual analogue scale (where 0=worst and 100=best health status) was 69 (SD 20), ranging from 63 (SD 22) in Brazil to 75 (SD 21) in Mexico. EQ-5D dimension mostly impaired was pain and discomfort with only 20.3% reporting have no problems in that dimension, while 72% reported have no problems with self-care. SF-36 physical and mental component scores for the total sample were 39 (SD 9.8) and 45 (SD 11.4), respectively. Lower values were observed for the physical component in Brazil (34) and the mental component in Argentina and Colombia (44). The table below summarizes these results for each country analyzed. <h3>Conclusions</h3> RA affects both work performance and quality of life in a substantial proportion of patients. Although similar trends were shown among countries, Brazilian patients reported to be more affected in most of evaluated aspects. <h3>Disclosure of Interest</h3> R. Xavier Consultant for: Abbvie, Pfizer, Janssen, AstraZeneca, BMS and Roche, Speakers bureau: Abbvie, Pfizer, Janssen, AstraZeneca, BMS and Roche, J. Morales-Torres Consultant for: Abbvie, Amgen, Lilly; Merck; Novartis; Pfizer; Roche; Sanofi and Servier, Speakers bureau: Abbvie, Amgen, Lilly; Merck; Novartis; Pfizer; Roche; Sanofi and Servier, D. Ramos-Remus: None declared, P. Chalem Consultant for: Abbvie, J. Molina Grant/research support from: Abbvie, J. Duhau Grant/research support from: Abbvie, A. Perez-Gilbe Employee of: Abbvie, E. Carnide Employee of: Abbvie
THU0534 Joint Hypermobility in Oligoarticular Juvenile Idiopathic Arthritis
Authors: V. Cecchin, F. Sperotto, M. Balzarin, F. Vittadello, G. Martini, F. Zulian
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. Oligoarticular JIA (oJIA) is the most frequent subtype of JIA, it has often lower limb involvement, ANA positivity and high risk of anterior uveitis. <h3>Objectives</h3> Since we observed that patients with oligoarticular JIA frequently have joint hypermobility, we would like to explore if the presence of this condition may influence the clinical course, the immunologic characteristics and the outcome of oJIA. <h3>Methods</h3> Children with oligoarticular JIA, defined by the ILAR criteria<sup>1</sup>, followed at the Pediatric Rheumatology Unit of University of Padua, with at least two years of disease duration and complete clinical data available, have been evaluated from January to December 2014. Clinical and laboratory data at disease onset and at the last follow-up were collected. They included sex, age, presence of joint hypermobility, according to the Beighton9s score<sup>2</sup>, family history for joint hypermobility, disease activity, uveitis, ANA, treatment and outcome (Wallace criteria<sup>3</sup>). <h3>Results</h3> 274 oligoarticular JIA patients (224 F, 50 M), aged 11.5±4.5 years and followed for 6.6±3.8 years, entered the study. Age at disease onset was 4.9±3.2 years, 78.8% had persistent subtype and 21.2% extended one. Joint hypermobility was present in 72.3% of children at disease onset and in 55.8% at the last evaluation. Uveitis occurred in 20.8% and was less frequent in hypermobile children (p=0,005). At the last examination, 52.5% of hypermobile patients were off therapy (p&lt;0,05) and at 5 years follow-up 51.3% were in full clinical remission, 35.4% were in clinical remission on medication and only 13.3% had active arthritis (p&lt;0.05). <h3>Conclusions</h3> Joint hypermobility in Oligoarticular JIA is more frequent than in normal subjects and has a positive influence on the disease course and long term outcome. <h3>References</h3> Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton 2001. J Rheumatol 2004;31:390-392 Beighton P, Solomon L, and Soskolne CL. Articular mobility in an African population. Ann Rheum Dis. 1973; 32: 413–418 Wallace CA, Ruperto N, Giannini E et al. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31:2290-2294 <h3>Acknowledgements</h3> We acknowledge IL VOLO, no-profit Association for Rheumatic Diseases in Children, ONLUS, Padua, Italy for having supported the study with a dedicated grant. <h3>Disclosure of Interest</h3> None declared
Prevalence of attention deficit disorder, residual type, and other psychiatric disorders in patients with irritable colon syndrome
Authors: P H Wender, M Kalm
Journal: American Journal of Psychiatry (1983)

On the basis of the observations that chronic nonspecific diarrhea is a precursor of irritable colon syndrome and that chronic nonspecific diarrhea is associated with attention deficit disorder in childhood, the authors conducted a psychiatric diagnostic evaluation of 22 adults with irritable colon syndrome. Six (27%) of the patients received a diagnosis of attention deficit disorder, residual type, six (27%) were diagnosed as having dysthymic disorder, and five (23%) had had episodes of unipolar depression. The relationship between the presence of these disorders and greater severity of irritable colon syndrome was statistically significant.